Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Drug Discovery: Overview01:26

Drug Discovery: Overview

11.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.0K
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

232
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
232
Ligand Binding Sites02:40

Ligand Binding Sites

14.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Commentary on the fundamentals and development of artificial intelligence models in the life sciences and best research practices.

Journal of computer-aided molecular design·2026
Same author

Explainable artificial intelligence reveals divergent learning in pharmacophore-based hierarchical pooling graph neural networks.

Scientific reports·2026
Same author

Categorization of Protein Kinases by Combining Data from Cell Biology and Medicinal Chemistry Enables Further Evaluation and Differentiation of the Understudied Kinome.

Journal of medicinal chemistry·2026
Same author

Transformer Learning in Sequence-Based Drug Design Depends on Compound Memorization and Similarity of Sequence-Compound Pairs.

Molecular informatics·2026
Same author

Identifying and evaluating understudied protein kinases using biological and chemical criteria.

RSC medicinal chemistry·2025
Same author

Comparing Explanations of Molecular Machine Learning Models Generated with Different Methods for the Calculation of Shapley Values.

Molecular informatics·2025

関連する実験動画

Updated: Jan 15, 2026

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.6K

医薬品研究における分子設計のための説明可能な人工知能

Alec Lamens1,2, Jürgen Bajorath1,2

  • 1Department of Life Science Informatics and Data Science, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, University of Bonn Friedrich-Hirzebruch-Allee 5/6 D-53115 Bonn Germany bajorath@bit.uni-bonn.de +49-228-7369-100.

Chemical science
|January 14, 2026
PubMed
まとめ

説明可能なAI（XAI）は、分子設計における機械学習（ML）予測の理解に不可欠です。ドメイン知識の統合は、創薬におけるより良いモデル洗練と実験設計のためのXAIを強化します。

キーワード:
説明可能なAI分子設計機械学習創薬ドメイン知識

さらに関連する動画

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.6K
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

941

関連する実験動画

Last Updated: Jan 15, 2026

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.6K
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.6K
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

941

科学分野:

  • 人工知能
  • 分子設計
  • 計算化学

背景:

  • 機械学習（ML）モデル、特にディープラーニングは、分子設計を進歩させています。
  • これらのMLモデルの「ブラックボックス」性質は、その予測の理解と受容を妨げます。
  • 説明可能なAI（XAI）は、特に実験科学において、このギャップを埋めるために不可欠です。

研究 の 目的:

  • 分子設計におけるXAIの課題と機会を調査すること。
  • XAIへのドメイン固有知識の組み込みの利点を評価すること。
  • 分子設計のための化学言語モデルの評価における限界を議論すること。

主な方法:

  • 分子設計の文脈における現在のXAI手法のレビュー。
  • XAIのためのドメイン固有知識の統合の分析。
  • 化学言語モデルの評価に関する議論。

主要な成果:

  • XAI手法は、人間中心で、透明性が高く、解釈可能な説明を提供する必要があります。
  • ドメイン知識は、MLモデルを洗練し、実験設計を支援し、仮説検証をサポートすることができます。
  • 分子設計における化学言語モデルの現在の評価方法は限られています。

結論:

  • XAIは、分子設計におけるMLの実用的な応用に不可欠です。
  • ドメインの専門知識でXAIを調整することが、その潜在能力を最大限に引き出す鍵となります。
  • 創薬におけるAIツールの堅牢な評価のためのさらなる開発が必要です。